000136191 001__ 136191
000136191 005__ 20240719195438.0
000136191 0247_ $$2doi$$a10.1007/s00345-024-05092-0
000136191 0248_ $$2sideral$$a139106
000136191 037__ $$aART-2024-139106
000136191 041__ $$aeng
000136191 100__ $$aMorote, Juan
000136191 245__ $$aExternal validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors
000136191 260__ $$c2024
000136191 5060_ $$aAccess copy available to the general public$$fUnrestricted
000136191 5203_ $$aPurpose : To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI).
Materials and methods : A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2.
Results: The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users.
Conclusions
The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.
000136191 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666
000136191 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000136191 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000136191 700__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, Ángel$$uUniversidad de Zaragoza
000136191 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis M.
000136191 700__ $$aPicola, Natàlia
000136191 700__ $$aMuñoz-Rodriguez, Jesús
000136191 700__ $$aPaesano, Nahuel
000136191 700__ $$aRuiz-Plazas, Xavier
000136191 700__ $$aMuñoz-Rivero, Marta V.
000136191 700__ $$aCelma, Ana
000136191 700__ $$aManuel, Gemma García-de
000136191 700__ $$aMiró, Berta
000136191 700__ $$aAbascal, José M.
000136191 700__ $$aServian, Pol
000136191 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología
000136191 773__ $$g42, 393 (2024), [8 pp.]$$pWorld j. urol.$$tWorld journal of urology$$x0724-4983
000136191 8564_ $$s2026375$$uhttps://zaguan.unizar.es/record/136191/files/texto_completo.pdf$$yVersión publicada
000136191 8564_ $$s2172832$$uhttps://zaguan.unizar.es/record/136191/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000136191 909CO $$ooai:zaguan.unizar.es:136191$$particulos$$pdriver
000136191 951__ $$a2024-07-19-18:28:59
000136191 980__ $$aARTICLE